ARTHRITIS  SPORTS INJURIES MUSCLE STRAINS MUSCLE SPRAINS   MUSCLE CRAMPS MINOR BACKACHE BRUISES  TENDINITIS BURSITIS NEURALGIA

CLINICAL STUDY

SorAlev™ is a proprietary topical formula designed to relieve the pain and inflammation associated with various forms of arthritis and other musculoskeletal injury.  A physician specializing in occupational medicine evaluated the SorAlev formula in comparison with ibuprofen and the leading topical pain reliever. These are abstracts from his report:

INTRODUCTION

SorAlev; a unique proprietary topical composition, was compared with ibuprofen, an NSAID (non-steroidal anti-inflammatory drug) and (Best-Selling topical*) the standard counter-irritant for the treatment of arthritis. 

Surprisingly. SorAlev was substantially more effective than either ibuprofen or the topical at relieving arthritis pain. Equally interesting, was the fact that SorAlev lasted longer and had a more rapid onset of action than either ibuprofen or (Best-Selling topical*).

Arthritis and the pain associated with arthritis are among the more common afflictions of mankind.  Therefore, any novel treatment with a salutary effect is worthy of consideration. SorAlev contains a patented molecule capable of enhancing penetration of active ingredients and enhancing anti-inflammatory responses, thereby reducing pain and discomfort and enhancing joint mobility. 

To determine relative efficacy, we did comparison testing of SorAlev, ibuprofen and (Best-Selling topical*). Ibuprofen is the largest selling NSAID in the world at the present time, and (Best-Selling topical*) is the largest selling topical counter-irritant for the treatment of arthritis.

METHODS & MATERIALS

A cohort of ten patients, all of whom had been diagnosed with clinically obvious osteoarthritis were enlisted in this study. Ages ranged from 45 to 78 years old. Half of the subjects were men and half were women. Grip strengths were determined prior to testing with a mercury-filled sphygmomanometer. Results were averaged among the ten patients.

Patients were asked to evaluate their pain in the morning on a scale of 1-10 with 10 being the most painful. These results were also averaged.  The various treatments were given for one week and the previous indices were re-evaluated at the end of the week.  One week of no medication was required in between tests.  This was done to avoid the possibility of therapeutic overlap.  The testing lasted for a total period of 6 weeks.

Ibuprofen was tested first and was administered orally in a standard dose of 400mg 2x/day. One subject complained of gastric irritation.  One subject complained of dizziness.  No one stopped taking the medication.

Best-selling topical*) was tested next and was administered topically to the affected joints, 3X/day.  Four of the subjects complained of skin irritation by the end of the week and two of these subjects had to reduce their administration of the product to twice daily.  No one stopped administering the product.

The third and final study was done using SorAlev.  Subjects were instructed to apply SorAlev to affected joints 3X/day.  There were no complaints of side effects and no one stopped administering SorAlev.

RESULTS:

A. Mercury Sphygmomanometer determination of grip strength in mm Hg averaged over the ten patients:

I.   Baseline     62 mm Hg.

II.  Ibuprofen      80 mm Hg.

III. (Best-Selling topical*)    71 mm Hg.

IV.  SorAlev     84 mm Hg.

B. Pain scale gradation in the morning on a scale of 1-10, with 10 being the most painful:

I.   Baseline   7.8

II   Ibuprofen    3.0

III  (Best-Selling topical*)  5.6

IV.  SorAlev    2.8

DISCUSSION:

Clearly, analysis of the results indicates that SorAlev has a substantial effect on arthritis. Certainly, the author has never in his prior experience encountered a topical preparation that exceeds the efficacy of an NSAID.

Equally intriguing to the author was the fact that all patients requested the opportunity to continue the use of SorAlev even if they had to pay for it.

However, the most intriguing aspect of this trial was the progressive improvement in joint mobility noticed after one week of treatment with SorAlev.  This was not noted with either ibuprofen or (Best Selling topical*) and certainly was not expected.  Two of the subjects were able to completely close their hands and make a fist, something that neither had been able to do for more than five years.

CONCLUSION:

SorAlev is a remarkably effective topical treatment for chronic osteoarthritis.  Further study involving patients with rheumatoid arthritis would be worthwhile.  However, it is this researcher's contention that the results would be expected to be similar to those encountered with osteoarthritis.

SorAlev™ is a trademark of Nature's Balance, Inc.

*NOTE: (Best-Selling topical*) Due to legal advice each reference to the trademark-protected identity of the topical counter-irritant used for comparative purposes in this study has been removed.

 

HEALTH PROFESSIONALS AND RETAIL OUTLETS PLEASE CALL 1-800-858-5198 FOR
 WHOLESALE PRICING INFORMATION, OR E-MAIL US at info@natures-balance.com

This page created and maintained by Nature's Balance, Inc. All text layout and photographic images are the copyright (©1995-2005) of Nature's Balance, Inc, and may not be copied or redistributed in any form without written consent from the owners. Contact our Webmaster